Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Dec;16(6):4578-4584.
doi: 10.3892/etm.2018.6773. Epub 2018 Sep 19.

Efficacy and safety of tiotropium bromide combined with budesonide/formoterol in the treatment of moderate to severe chronic obstructive pulmonary disease

Affiliations

Efficacy and safety of tiotropium bromide combined with budesonide/formoterol in the treatment of moderate to severe chronic obstructive pulmonary disease

Daguo Zhao et al. Exp Ther Med. 2018 Dec.

Abstract

With the increase of environmental pollution, chronic obstructive pulmonary disease (COPD) has become a serious health threat. In the present study, the efficacy and safety of inhalation therapy of tiotropium bromide combined with budesonide/formoterol were assessed in 180 patients with moderate to severe COPD (clinical trial registry no. ChiCTR1800017584). Patients were treated by inhalation of budesonide/formoterol (control group) or inhalation of tiotropium bromide combined with budesonide/formoterol (intervention group). The results indicated that after the treatment, the forced expiratory volume in 1 sec, the modified Medical Research Council scale, the 6-min walking distance and the St. George's Respiratory Questionnaire scores for quality of life were significantly improved in the two groups, while the improvements in the intervention group were more significant (all P<0.05). There was no significant difference in body mass indices between the two groups during the course of the treatment (P=0.302). The difference in the risk of an acute exacerbation between the two groups was also not significant (P=0.238). The median time to the first acute exacerbation from the start of treatment in the intervention group (53 days; 25% quartile, 50 days; 75% quartile, 62 days) was significantly longer than that in the control group (37 days; 25% quartile, 23 days; 75% quartile, 39 days; P=0.042). The adverse reaction rates in the intervention and control groups were 14.4 and 10.0%, respectively, without any significant difference. In conclusion, inhalation treatment of tiotropium bromide combined with budesonide/formoterol significantly improves pulmonary function, exercise capacity and quality of life of patients with COPD compared with budesonide/formoterol inhalation alone, while the effect of reducing the acute attack risk requires further evaluation.

Keywords: budesonide; chronic obstructive pulmonary disease; efficacy; formoterol; safety; tiotropium bromide.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Risk of acute attack in the two groups. There was no significant difference in the risk of acute exacerbation between the two groups during the study (log rank test P=0.238). COPD, chronic obstructive pulmonary disease.
Figure 2.
Figure 2.
Median time to the first exacerbation since the start of the treatment in the two groups. The median time to the first exacerbation in the intervention group (53 days; 25% quartile, 50 days; 75% quartile, 62 days) was significantly longer than that in the control group (37 days; 25% quartile, 23 days; 75% quartile, 39 days; P=0.042).

References

    1. Yin P, Wang H, Vos T, Li Y, Liu S, Liu Y, Liu J, Wang L, Naghavi M, Murray CJ, Zhou M. A subnational analysis of mortality and prevalence of COPD in China From 1990 to 2013: Findings from the global burden of disease study 2013. Chest. 2016;150:1269–1280. doi: 10.1016/j.chest.2016.08.1474. - DOI - PubMed
    1. Guan WJ, Ran PX, Zhong NS. Prevention and management of COPD in China: Successes and major challenges. Lancet Respir Med. 2016;4:428–430. doi: 10.1016/S2213-2600(16)30092-3. - DOI - PubMed
    1. COPD Group of Chinese Thoracic Society: Guidelines for the diagnosis and treatment of chronic obstructive pulmonary disease (2013 revised edition), corp-author Chin J Tuberculosis Respiratory Dis. 2013;4:255–264. (In Chinese)
    1. Tunks M, Miller D. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease-2008 update-highlights for primary care. Can Respir J. 2008;15:219. doi: 10.1155/2008/851415. - DOI - PMC - PubMed
    1. Jung KS, Park HY, Park SY, Kim SK, Kim YK, Shim JJ, Moon HS, Lee KH, Yoo JH, Lee SD, et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: A randomized controlled study. Respir Med. 2012;106:382–389. doi: 10.1016/j.rmed.2011.09.004. - DOI - PubMed